Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
International Journal of Pharmaceutics|January 9, 2020
Developing an injectable co-formulation of two antidiabetic drugs: Excipient impact on peptide aggregation and pharmacokinetic propertiesAnne-Laure Lainé, Sophie Houvenagel, Anders Broo, et al.
Molecular Cancer|February 15, 2013
Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell typeSteven Rust, Sandrine Guillard, Kris Sachsenmeier, et al.
Lancet (London, England)|June 28, 2018
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a studyPhilip Ambery, Victoria E Parker, Michael Stumvoll, et al.
Contemporary Clinical Trials Communications|February 7, 2025
Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN studySamuel J Daniels, Karin Nelander, John Eriksson, et al.
The Journal of Applied Laboratory Medicine|July 7, 2022
The Common H202D Variant in GDF-15 Does Not Affect Its Bioactivity but Can Significantly Interfere with Measurement of Its Circulating LevelsYanislava Karusheva, Matthew Ratcliff, Alexander Mörseburg, et al.
Diabetes, Obesity & Metabolism|April 2, 2024
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesityRajna Golubic, Jane Kennet, Victoria Parker, et al.
Chemistry & Biology|November 10, 2015
Combinatorial Screening Identifies Novel Promiscuous Matrix Metalloproteinase Activities that Lead to Inhibition of the Therapeutic Target IL-13Carole Urbach, Nathaniel C Gordon, Ian Strickland, et al.
American Journal of Physiology. Renal Physiology|July 22, 2016
Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney diseaseMarcela Herrera, Magnus Söderberg, Alan Sabirsh, et al.
British Journal of Clinical Pharmacology|September 30, 2025
An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon-like peptide-1 and glucagon receptor in healthy subjectsJames Goodman, Victoria E Parker, Carmel M McEniery, et al.
The Journal of Biological Chemistry|December 21, 2016
Apelin-36 Modulates Blood Glucose and Body Weight Independently of Canonical APJ Receptor SignalingHadas Galon-Tilleman, Hong Yang, Maria A Bednarek, et al.
Pageof 7